EUCTR2019-001318-40-GB进行中（未招募）1 期
A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SN38-SPL9111 (DEP®-SN38), a SN38 dendrimer conjugate, in patients with advanced solid tumours. - SN38-SPL9111 in advanced solid tumours
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 149
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Signed informed consent form.
- •2.At least 18 years old.
- •3. Patients with histologically or cytologically confirmed advanced or metastatic cancer for which no standard therapy is available and who in the opinion of the investigator, could potentially benefit from treatment with irinotecan or SN38-SPL9111. For phase 2 dose expansion, preference will be given to patients with colorectal, pancreatic, ovarian, upper gastrointestinal and breast cancers. Patients may also be irinotecan naïve. Exceptionally, tumours in other locations may be enrolled subject to sponsor approval.
- •4. Willing to be tested for uridine diphosphate-glucuronosyl transferase 1 family, polypeptide A1 (UGT1A1) genotype (if this result is not already available).
- •5. Measurable disease per RECIST version 1.1 or applicable radiological or biochemical assessment. In the dose escalation/ assessment parts, patients with measurable or evaluable disease will be enrolled; in the dose expansion parts, only patients with measurable disease will be enrolled.
- •6.Adequate bone marrow reserve as demonstrated by an absolute neutrophil count (ANC) = 1.5 × 109/L or platelet count = 100 × 109/L (cannot be post-transfusion) or haemoglobin = 9 g/dL (can be post-transfusion).
- •7.Serum bilirubin < 1.5 x upper limit of normal (ULN)
- •8.Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level < 2.5 × ULN or < 5x ULN for patients with liver metastases
- •9.Serum creatinine < 1.5 × ULN; however, an exception can be made if the calculated (by the Cockcroft-Gault formula) or measured creatinine clearance is > 50 mL/min.
- •10.Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- •11.Life expectancy of greater than 12 weeks.
- •12.Reproductive inclusion criteria:
- •a)If of childbearing potential, willing to use an effective form of contraception (see below) during chemotherapy treatment and for at least six months thereafter.
- •Such methods include (if using hormonal contraception this method must be supplemented with a barrier method, preferably male condom):
- •combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
- •ointravaginal
- •otransdermal
- •progestogen-only hormonal contraception associated with inhibition of ovulation:
- •oinjectable
- •oimplantable
- •intrauterine device (IUD)
- •intrauterine hormone-releasing system (IUS)
- •bilateral tubal occlusion
- •vasectomised partner
- •true sexual abstinence when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception.
- •b) Women must have a negative pregnancy test at study entry.
- •c) Men who are truly sexually abstinent when this is in line with the preferred and usual lifestyle of the subject or vasectomized or willing to ensure that their female sexual partners use a highly-effective means of contraception (i.e. as outlined in Inclusion criterion 12.a.) for the duration of study therapy and 6 months afterwards. In addition, men must be willing to use a condom during sexual intercourse from the first dose of SN38-SPL9111 until 6 months after their final dose, so as to protect their partner from exposure to study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age ra
排除标准
- •1.Uncontrolled brain metastases or spinal cord compression. Patients who were treated with surgical resection or radiation therapy completing at least 4 weeks earlier are eligible if they are neurologically stable and have a follow-up Magnetic Resonance Imaging (MRI) scan performed within the previous 4 weeks showing no tumour progression.
- •2.Patients homozygous for the UGT1A1*28 allele (Gilbert syndrome) or patients with a congenital deficiency of UGT1A1 (Crigler-Najjar syndrome) will be excluded from the Phase 1 dose-escalation/ dose assessment part of the study; they may be enrolled in the Phase 2 dose expansions part starting at a reduced dose and incrementing to the full recommended dose, if no excessive toxicity is encounted.
- •3.History of an untreated bleeding diathesis.
- •4.Active bowel obstruction, history of inflammatory bowel disease or chronic or acute gastrointestinal disorders with diarrhoea as a major symptom.
- •5.Allergy/hypersensitivity to irinotecan and SN38-containing preparations, pegylated drugs or other components of study therapy or compounds of similar chemical composition.
- •6.Myocardial infarction within 6 months of enrolment, congestive heart failure of New York Heart Association class > II, unstable angina or unstable cardiac arrhythmias.
- •7. Other uncontrolled intercurrent illness, including active infection.
- •8. Participation in a study of an investigational agent within 30 days prior to first dose of study therapy.
- •9. Anti-tumour therapy (including chemotherapy, radiation therapy, targeted therapeutics or hormonal therapy) within 28 days or 5-half-lives (whichever is shorter) prior to first study therapy.
- •10. Cumulative dose of corticosteroid = 150 mg prednisone (or equivalent doses of corticosteroids) within two weeks of the first IMP administration.
- •11. Unresolved toxicity from prior anti-tumour therapy, defined as toxicities (excluding alopecia) that have not resolved to < grade 2 or baseline as scored using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Exceptions may be allowed for stable toxicities after investigator discussion with the Medical Monitor and sponsor.
- •12. Major surgery within 28 days of commencing first dose of study therapy.
- •13. Pregnant or breast-feeding females.
- •14. Concurrent or planned treatment with strong inhibitors of UDP-Glucuronosyl transferase 1A1 (UGT1A1) (e.g., atazanavir, gemfibrozil, indinavir). A 1-week washout period is necessary for patients already on these treatments.
- •15. Any concurrent, clinically significant condition which, in the Investigator's opinion, makes it undesirable for the subject to participate in this study or which would jeopardize compliance with the protocol.
研究者
相似试验
进行中（未招募）
1 期
A phase 1/2 study in which, DTX-SPL8783, the trial medication will beadministered (alone or in combination with nintedanib) in order to assess the safety, tolerability, pharmacokinetics (distribution of DTX-SPL8783 in the body) and efficacy in patients with advanced malignant tumours.ocally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC).MedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864EUCTR2016-000877-19-GBStarpharma Pty Ltd.65
进行中（未招募）
1 期
A phase 1/2 study in which, CTX-SPL9111, the trial medication will be administered to evaluate the safety, tolerability, pharmacokinetics (distribution of CTX-SPL9111 in the body) and efficacy in patients with advanced solid tumoursPatients with advanced solid tumoursMedDRA version: 20.0 Level: LLT Classification code 10007050 Term: Cancer System Organ Class: 100000004864EUCTR2017-003424-76-GBStarpharma Pty Ltd33
招募中
1 期
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-C3 in Adult Healthy Volunteers and in Adult Patients With Complement-Mediated Renal Diseasecomplement-mediated renal diseaseMedDRA version: 23.0Level: PTClassification code: 10083522Term: Immune-mediated renal disorder Class: 100000004857CTIS2023-506690-36-00Arrowhead Pharmaceuticals Inc.69
进行中（未招募）
1 期
Study of ARO-DUX4 in Adult Patients With Facioscapulohumeral Muscular Dystrophy Type 1CTIS2023-509748-89-00Arrowhead Pharmaceuticals Inc.70
进行中（未招募）
1 期
A clinical gene therapy study with hematopoietic stem cells for the treatment of patients suffering from a malignant neoplasm of the central nervous systemGlioblastoma MultiformeEUCTR2018-001404-11-ITGENENTA SCIENCE SR21